82 related articles for article (PubMed ID: 6200390)
41. Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204.
Amadori S; Ceci A; Comelli A; Madon E; Masera G; Nespoli L; Paolucci G; Zanesco L; Covelli A; Mandelli F
J Clin Oncol; 1987 Sep; 5(9):1356-63. PubMed ID: 3476689
[TBL] [Abstract][Full Text] [Related]
42. Fractional administration of adriblastin and modified route of ara-C administration for the treatment of acute leukaemia.
Hołowiecki J; Jarczok K; Duraj M; Rudzka E; Krzemień S; Krawczyk M; Hołowiecka B; Opala G; Jagoda K; Pawelski S
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(5):689-97. PubMed ID: 2416645
[TBL] [Abstract][Full Text] [Related]
43. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
Lazarus HM; Vogler WR; Burns CP; Winton EF
Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
[TBL] [Abstract][Full Text] [Related]
44. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
[TBL] [Abstract][Full Text] [Related]
45. Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.
Liang R; Chiu E; Chan TK; Todd D
Cancer Chemother Pharmacol; 1990; 26(5):380-2. PubMed ID: 2208581
[TBL] [Abstract][Full Text] [Related]
46. Selective use of daunorubicin for remission-induction chemotherapy in acute non-lymphoblastic leukemia.
Shaikh BS; Dougherty JB; Hamilton RW; Ballard JO; Patel SB; Gevirtz NR; Eyster ME
Cancer; 1980 Oct; 46(8):1731-4. PubMed ID: 6932996
[TBL] [Abstract][Full Text] [Related]
47. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
[TBL] [Abstract][Full Text] [Related]
48. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Wiernik PH; Glidewell OJ; Hoagland HC; Brunner KW; Spurr CL; Cuttner J; Silver RT; Carey RW; DelDuca V; Kung FH; Holland JF
Med Pediatr Oncol; 1979; 6(3):261-77. PubMed ID: 381887
[TBL] [Abstract][Full Text] [Related]
49. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia.
Kantarjian HM; Keating MJ; Walters RS; McCredie KB; Bodey GP; Freireich EJ
Cancer; 1986 Oct; 58(8):1603-8. PubMed ID: 3463390
[TBL] [Abstract][Full Text] [Related]
50. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug.
Marie JP; Wdowik T; Bisserbe S; Zittoun R
Leukemia; 1992 Jul; 6(7):720-2. PubMed ID: 1625492
[TBL] [Abstract][Full Text] [Related]
51. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
Jehn U; Knüppel W; Wilmanns W
Onkologie; 1988 Feb; 11(1):13-7. PubMed ID: 3283620
[TBL] [Abstract][Full Text] [Related]
52. [A trial administration of small doses of Ara-C as a second step in remission induction in patients with acute non-lymphocytic leukemia].
Nakayama S; Nagai K; Yoshida T; Yabe H
Rinsho Ketsueki; 1985 Mar; 26(3):423-8. PubMed ID: 3861889
[No Abstract] [Full Text] [Related]
53. [Results of treatment of acute myeloid leukemia in adults].
Nowrousian MR; Kubaschinski G; Hossfeld DK; Schaefer UW; Schmidt CG
Onkologie; 1983 Aug; 6(4):184-6. PubMed ID: 6355947
[TBL] [Abstract][Full Text] [Related]
54. High-dose daunorubicin (DNR) for induction and treatment of relapse in acute promyelocytic leukemia (APL): report of 17 cases.
Bobbio Pallavicini E; Luliri P; Anselmetti L; Gorini M; Invernizzi R; Ascari E
Haematologica; 1988; 73(1):48-53. PubMed ID: 3163667
[No Abstract] [Full Text] [Related]
55. [AML-7 study of the value of intensive remission induction in aged patients with acute myelocytic leukemia].
Jehn U; Löwenberg B
Onkologie; 1985 Apr; 8(2):97-8. PubMed ID: 3889758
[TBL] [Abstract][Full Text] [Related]
56. [AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Jehn U; Zittoun R
Onkologie; 1985 Apr; 8(2):94-5. PubMed ID: 2582325
[TBL] [Abstract][Full Text] [Related]
57. Treatment of acute myeloid leukaemia in children.
Paton CM; Ekert H; Waters KD; Matthews RN; Toogood IR
Aust N Z J Med; 1982 Apr; 12(2):143-6. PubMed ID: 6953955
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
Kokenberg E; van der Steuijt K; Löwenberg B; Nooter K; Sonneveld P
Haematol Blood Transfus; 1987; 30():283-7. PubMed ID: 3476358
[TBL] [Abstract][Full Text] [Related]
59. ACTH 1-17 effects in acute myeloid leukemia.
Arcese W; Nervi C; Avvisati G; Mandelli F
Ric Clin Lab; 1984; 14(2):199-203. PubMed ID: 6091244
[TBL] [Abstract][Full Text] [Related]
60. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.
Yates J; Glidewell O; Wiernik P; Cooper MR; Steinberg D; Dosik H; Levy R; Hoagland C; Henry P; Gottlieb A; Cornell C; Berenberg J; Hutchison JL; Raich P; Nissen N; Ellison RR; Frelick R; James GW; Falkson G; Silver RT; Haurani F; Green M; Henderson E; Leone L; Holland JF
Blood; 1982 Aug; 60(2):454-62. PubMed ID: 6953986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
